-
公开(公告)号：US20230190816A1
公开(公告)日：2023-06-22
申请号：US17790597
申请日：2020-11-26
Inventor： Akihiko TAGUCHI , Yuko OGAWA , Yuka OKINAKA , Masanori FUKUSHIMA , Atsuo YAMANAKA
CPC classification number: A61K35/28 , A61P9/10 , A61P25/00 , A61K2035/124
Abstract: The effect of physical exercise performed on a physical function of a subject with an irreversibly reduced physical function is promoted. Bone marrow mononuclear cells, CD34-positive cells, CD133-positive cells, or stem cells are contained. The central and peripheral nerves communicate intimately with each other. When these cells are administered to a subject, and the subject performs an appropriate physical exercise, the reduced physical function can be dramatically improved. The physical exercise .is, for example, physical exercise that stimulates both of brain and peripheral nerves based on the interactive biofeedback theory. Thus, for example, when bone marrow mononuclear cells are administered to a patient with a sequela of cerebral infarction, and the patient performs an appropriate physical exercise, the effect of functional recovery from the sequela of the cerebral infarction is promoted.
-
公开(公告)号：US20210047385A1
公开(公告)日：2021-02-18
申请号：US16966232
申请日：2019-01-31
Applicant: KINKI UNIVERSITY , AINO UNIVERSITY , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Inventor： Koichi MORIMOTO , Saori KUNII , Kenji KANEKIYO , Norihiko NAKANO , Chizuka IDE , Kaoru OMAE
IPC: C07K14/78 , C12N5/0793 , A61K38/39 , A61P25/00
Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.
-
公开(公告)号：US20240150421A1
公开(公告)日：2024-05-09
申请号：US18546066
申请日：2022-02-09
Applicant: NAGASAKI UNIVERSITY , Foundation for Biomedical Research and Innovation at Kobe , National Institutes for Quantum Science and Technology
Inventor： Yoshimasa TANAKA , Shun SAKURABA
IPC: C07K14/54 , A61K38/20 , C12N5/0783
CPC classification number: C07K14/54 , A61K38/2013 , C12N5/0636 , A61K2039/505
Abstract: A novel interleukin-18 (IL-18) variant and a pharmaceutical composition using the same, which relates to a human IL-18 variant including (i) mutations of cysteine at positions 38, 68, 76, and 127 into serine and (ii) mutations of glutamic acid at position 6 and lysine at position 53 into alanine relative to an amino acid sequence of wild-type human IL-18, where the variant further includes (iii) at least one additional mutation, and a pharmaceutical composition containing the human IL-18 variant.
-
公开(公告)号：US11744858B2
公开(公告)日：2023-09-05
申请号：US15558999
申请日：2016-03-18
Inventor： Akihiko Taguchi , Kenichi Yamahara , Yukiko Niino
IPC: A61K35/14 , A61P9/10 , A61K35/28 , A61K45/00 , A61K38/48 , A61K38/22 , A61K38/46 , A61P13/12 , A61K38/17 , A61K38/18 , C12N5/00
CPC classification number: A61K35/14 , A61K35/28 , A61K38/1709 , A61K38/1825 , A61K38/1841 , A61K38/1858 , A61K38/1866 , A61K38/22 , A61K38/46 , A61K38/48 , A61K38/4886 , A61K45/00 , A61P9/10 , A61P13/12 , C12N5/0087 , C12Y304/24024
Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.
-
5.发明公开公开(公告)号：US20230183347A1
公开(公告)日：2023-06-15
申请号：US17923996
申请日：2021-05-24
Applicant: Foundation for Biomedical Research and Innovation at Kobe , National Institutes of Biomedical Innovation, Health and Nutrition , Meiji Seika Pharma Co., Ltd.
Inventor： Tasuku Honjo , Akio Ohta , Masaki Tajima , Haruhiko Kamada , Satoshi Nagata , Kensuke Suzuki , Yuya Oshiro , Yosuke Tokumaru
CPC classification number: C07K16/2818 , A61P37/08
Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.
-
Patent Agency Ranking
公开(公告)号：US20230021187A1
公开(公告)日：2023-01-19
申请号：US17777846
申请日：2020-11-18
Inventor： Minako HOSHI , Yoshie ARAI , Kiyotaka MACHIDA
IPC: C07K14/47 , G01N33/531 , G01N33/68 , G01N33/547
Abstract: A substance that can be a substitute for amylospheroids (ASPD) and a method for analyzing ASPD are provided. Viewed from one aspect, the present disclosure relates to a substance in which amyloid-β protein (Aβ) is cross-linked with a cross-linking agent that has a spacer arm length of between 4 Å and 50 Å inclusive or a cross-linking agent that has, as a spacer arm, not less than 1 and not more than 13 groups that are an oxyethylene group(s) (—CH2CH2O—) and/or an oxypropylene group(s) (—CH2CH2CH3O—). Viewed from another aspect, the present disclosure relates to a method for analyzing ASPD using the substance as a reference material.
-
公开(公告)号：US20230263740A1
公开(公告)日：2023-08-24
申请号：US18310999
申请日：2023-05-02
Applicant: KEIO UNIVERSITY , Foundation for Biomedical Research and Innovation at Kobe , MORISHITA JINTAN CO., LTD.
Inventor： Takanori KANAI , Hideo NISHIMURA , Tomoyuki KOYAMA , Takuhiko ADACHI , Hiroyuki HAYAKAWA
IPC: A61K9/48 , A61P1/04 , A61K31/404
CPC classification number: A61K9/4891 , A61P1/04 , A61K9/4866 , A61K9/4875 , A61K31/404
Abstract: An object of the present invention is to obtain a capsule for treating ulcerative colitis which, when a capsule containing indigo is orally administered, acts more effectively than conventional ones and has less side effects of hepatotoxicity by not easily disintegrating in the stomach and small intestine but only in the large intestine. The present invention relates to a capsule for treating ulcerative colitis which disintegrates locally in the large intestine, comprising a drug-containing content, a protective layer coating the content and a film formed outside the protective layer, which are arranged concentrically, wherein the content is a content in which indigo, which is a drug for treating ulcerative colitis, is dispersed or dissolved, and the film is locally disintegrated in the large intestine.
-
8.发明授权公开(公告)号：US11219672B2
公开(公告)日：2022-01-11
申请号：US15501760
申请日：2015-08-07
Applicant: Haruki Okamura , Kyosuke Yamanishi , Yoshimasa Tanaka , MEDICAL RESEARCH AND DEVELOPMENT CORPORATION , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Inventor： Haruki Okamura , Kyosuke Yamanishi , Wen Li
Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.
-
公开(公告)号：US20210198307A1
公开(公告)日：2021-07-01
申请号：US16771781
申请日：2018-12-14
Inventor： Yo-ichi NABESHIMA , Yoko NABESHIMA , Chiaki ABE
Abstract: The purpose of the present invention is to provide a method for producing active GcMAF more simply and at a high yield. The present invention is a method for producing active GcMAF comprising a step for culturing host cells which are transfected with a VDBP expression vector in serum-free medium. This culture is preferably a suspension culture. In addition, this method for producing active GcMAF is also characterized by not requiring an enzyme treatment step for deglycosylation.
-
公开(公告)号：US20210100790A1
公开(公告)日：2021-04-08
申请号：US17126488
申请日：2020-12-18
Applicant: Tadamasa MATSUMOTO , NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Inventor： Tadamasa MATSUMOTO , Masafumi IHARA , Satoshi SAITO , Masanori FUKUSHIMA
IPC: A61K31/4709 , A61K31/353 , A61P25/28
Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.021 seconds)
